Spyre Therapeutics, Inc.
SYRE
$75.77
$0.730.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -54.12% | -11.07% | 83.80% | 5.46% | -2.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 162.00% | 143.61% | -208.95% | -114.01% | -63.29% |
| Change in Net Operating Assets | 142.96% | -120.98% | -42.61% | 68.99% | -116.35% |
| Cash from Operations | -39.95% | -19.84% | -26.16% | 25.20% | -43.63% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 92,855.74% | -40.97% | -41.51% | 159.74% | 99.94% |
| Cash from Investing | 92,855.74% | -45.07% | -41.51% | 165.55% | 99.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5,600.00% | 38.49% | -96.25% | 47.68% | -95.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -83.87% | 78.96% | -6,482.05% | -- | 93.50% |
| Cash from Financing | 9,704.00% | 38.66% | -136.33% | 103.06% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.01% | 16.71% | -164.19% | 118.18% | -205.88% |